Petra is a leading clinical-stage pharmaceutical company developing a diverse portfolio of novel therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer.
PI pathways regulate fundamental processes of cellular growth and metabolism. The importance of PI signaling in human health is underscored by the many diseases that arise from PI pathways deregulation. PI-modifying enzymes are among the most frequently mutated proteins in cancer.
Building on new scientific insights, Petra is committed to advancing the promise of PI signaling pathways, opening new frontiers in biology to generate important and novel therapies for unaddressed medical needs.